EpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called EpiVax Oncology.
EpiVax Oncology Inc. is a newly created, wholly owned subsidiary of EpiVax Inc. EpiVax Oncology’s goal is to become the leading Neo-epitope based personalized cancer vaccine company, with the ultimate purpose to address major unmet medical needs inadequately addressed by other oncology and immune-oncology treatment approaches. EpiVax Oncology’s ambition is to become a premier cancer precision medicine company, leveraging EpiVax’s world class excellence in computational-immunology, genomics and vaccine design.
Click here to read the full Providence Business News article.